About the Company
We do not have any company description for Alector, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Alector, Inc.
After Golden Cross, Alector (ALEC)'s Technical Outlook is Bright
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
Alector Reports Second Quarter 2025 Financial Results and Provides Business Update
On track to report topline data by mid-Q4 2025 from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN, a severe, rare form of dementia with no approved treatments Ongoing Phase 2 ...
Alector Inc (ALEC) Q4 2024 Earnings Report Preview: What to Expect
Alector Inc (NASDAQ:ALEC) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue is $16.62 million, and the earnings are expected to come in at -$0.63 ...
Alector, Inc. Reports Q4 2024 Financial Results and Provides ... - Nasdaq
Alector, Inc. reported its fourth quarter and full year 2024 financial results, highlighting significant clinical developments in neurodegenerative disease therapies.
Broker Revenue Forecasts For Alector, Inc. (NASDAQ:ALEC) Are Surging ...
Following the upgrade, the current consensus from Alector's seven analysts is for revenues of US$36m in 2021 which - if met - would reflect a major 100% increase on its sales over the past 12 ...
Alector Initiates First-in-Human Dosing in Phase 1 Study of AL101 for ...
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that in December ...
Alector Nabs $205 Million Via Development Deal With AbbVie
AbbVie Inc. is betting big on Alector LLC’s new strategy for combatting Alzheimer’s disease. AbbVie, which previously backed Alector through AbbVie Ventures, is making a $205 million payment ...
Biotech Startup Alector Announces IPO Plans - WSJ
Biotech startup Alector Inc. on Monday revealed plans for an initial public offering to finance development of a series of neurological disease therapies. Alector’s approach to treating brain ...
Alector sets IPO terms to value company at up to $1.4 billion
Alector Inc. set terms for its initial public offering, which would value the immuno-neurology company at about $1.4 billion. The company is offering 9.25 million shares, which are expected to ...
Biotech Alector Drops as IPOs Restart After U.S. Shutdown
Alector Inc. fell in its trading debut after raising $176 million in the first U.S. initial public offering without a fixed share price since the government shutdown all but froze the market.
Biopharmaceutical Alector files for IPO - MarketWatch
Alector Inc. , a San Francisco-based clinical stage biopharmaceutical company, is seeking to raise millions in funds via an initial public offering, according to a filing submitted to the ...
Similar Companies
Loading the latest forecasts...